Why Is Inflammatory Disease-Focused ZyVersa Therapeutics Stock Trading Higher Today? - ZyVersa Therapeutics (NASDAQ:ZVSA)
ZyVersa reveals study in Acta Neuropathologica Communications. Learn how inhibiting NLRP3 inflammasome with Inflammasome ASC Inhibitor IC 100 prevents TNBC brain metastasis.
Stephen Glover Zyversa Therapeutics Co Acta Neuropathologica Communications Zyversa Therapeutics Co Founder Chief Executive Officer President Stephen Glover
Source: benzinga.com